Piramal Pharma Share News - Latest Updates, Live News & More

Latest news about Piramal Pharma

Piramal Pharma Sells Decommissioned Thane Unit to Global Pharma for Rs 8.50 Crores 4 days ago

Piramal Pharma Limited (PPL) has approved the sale of its non-operational unit in Thane to Global Pharma for approximately Rs. 8.50 crores, exclusive of taxes. The transaction is expected to close within 90 days. The decommissioned unit had no contribution to PPL's turnover, income, or net worth in the last financial year. This sale follows the termination of a previous agreement and is part of PPL's asset management strategy. The buyer is unrelated to PPL's promoter group, and the sale is not a Related Party Transaction.

CARE Ratings Upgrades Piramal Pharma's Credit Ratings to CARE AA with Stable Outlook 5 days ago

Piramal Pharma's Subsidiary Secures $2.4 Million Settlement from Astral Jul 04, 2025

Carlyle Group Plans to Offload Up to 10% Stake in Piramal Pharma Jul 03, 2025

Piramal Pharma's Aurora Facility Passes USFDA Inspection with Flying Colors Jun 02, 2025

More news about Piramal Pharma

16May 25

Piramal Pharma's Quarterly Results In Line with Expectations; Goldman Sachs Remains Bullish on Profit Growth Potential

Piramal Pharma Limited (PPL) received positive assessments from analysts following its recent quarterly performance. Goldman Sachs and Motilal Oswal maintained 'Buy' ratings on the stock. The company's sales and EBITDA met projections, though earnings fell short due to asset impairment. PPL aims for a 25% EBITDA margin by FY30, showcasing potential for top-quartile profit growth. The positive outlook could have broader implications for the Indian pharmaceutical sector.

14May 25

Piramal Pharma Reports Robust Q4 FY2023 Results with 48% Profit Surge

Piramal Pharma Limited announced strong financial results for Q4 FY2023. Net profit rose 48.51% year-over-year to ₹1.50 billion. Revenue increased by 7.76% to ₹27.50 billion. EBITDA grew to ₹5.60 billion, with a slight margin decline to 20.36%. The results showcase significant profit growth outpacing revenue growth, indicating improved operational efficiency.

13May 25

Piramal Pharma Invests $90 Million in US Facilities Expansion Amid Growing Demand

Piramal Pharma announces a $90 million investment to expand facilities in Lexington and Riverview, USA, responding to increased customer demand and onshoring trends. The Lexington expansion will be completed by 2027, while the Riverview project is set for 2025. Additionally, the company's Turbhe facility received an FDA Establishment Inspection Report with Voluntary Action Indicated status.

12May 25

Piramal Pharma Commits $90 Million for US Facility Expansions

Piramal Pharma announced a $90 million investment plan to expand two of its US manufacturing sites in Lexington, Kentucky and Riverview, Michigan. The expansion aims to enhance production capabilities for injectable drug products, addressing increased demand from US customers and the trend of onshoring drug supply. The Lexington site will add 24,000 square feet of new manufacturing space, with operations expected to commence by late 2027. This strategic move is designed to better serve the North American market and potentially increase Piramal's share in the sterile injectables segment.

02Apr 25

Piramal Pharma Expands Anesthesia Portfolio with Sevoflurane Production in Telangana

Piramal Pharma Limited (PPL) has begun commercial production of Sevoflurane, an inhalational anesthetic, at its Digwal, Telangana facility. This expansion complements their existing production in Bethlehem, Pennsylvania, USA. The move aims to tap into Rest of World (ROW) markets beyond the USA, enhancing PPL's global competitiveness in the anesthesia market. The dual manufacturing locations are expected to provide increased supply chain flexibility and wider market access.

21Mar 25

Piramal Critical Care's Neoatricon® Receives MHRA Approval for Pediatric Hypotension Treatment

Piramal Pharma Limited's Critical Care division announced MHRA approval for Neoatricon®, a novel pediatric formulation of Dopamine Hydrochloride for treating hypotension in neonates, infants, and children. Developed by BrePco Biopharma Limited, Neoatricon® is the first approved pediatric-strength solution for Dopamine Hydrochloride infusion. Piramal Critical Care has secured commercialization rights for the EU, UK, and Norway. The product offers age-appropriate formulations, improved safety, and enhanced efficiency in critical care settings.

20Mar 25

Piramal Critical Care's Neoatricon® Secures MHRA Approval for Pediatric Hypotension Treatment

Piramal Pharma Limited's Critical Care division has received MHRA approval for Neoatricon®, a pediatric formulation for treating hypotension in neonates, infants, and children. Developed with BrePco Biopharma, it's the first pediatric-strength Dopamine Hydrochloride solution for infusion. Available in two concentrations, Neoatricon® offers precise dosing, reduced preparation time, and minimizes risks associated with adult formulations. Piramal has secured commercialization rights in the EU, UK, and Norway, marking its expansion into a new therapeutic area.

18Feb 25

Piramal Pharma's Turbhe Facility Receives FDA Form-483 with Six Observations

Piramal Pharma Limited's Turbhe facility underwent a GMP inspection by the US FDA from February 11-17, 2025, resulting in a Form-483 with six observations. The company stated these observations are primarily for procedure improvements and not related to data integrity issues. Piramal Pharma is preparing a detailed response within the stipulated timelines. The company also announced changes to its Registrar and Share Transfer Agent, now MUFG Intime India Private Limited, and scheduled investor meetings in Hong Kong.